Since its 1998 FDA approval, trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used as an effective therapy for HER2+ BC alongside other drugs directly inhibiting HER2 activity [4]. Here, ERBB2 is linked to breast cancer.